Hipertiroidismo

  1. M. Toni 1
  2. J. Pineda 2
  3. E. Anda 2
  4. J.C. Galofré 2
  1. 1 Servicio de Endocrinología y Nutrición. Hospital García Orcoyen. Estella. Navarra. España
  2. 2 Instituto de Investigación Sanitaria de Navarra (IdiSNA). Pamplona. Navarra. España
Journal:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Year of publication: 2016

Issue Title: Enfermedades endocrinológicas y metabólicas (I) Patología del tiroides

Series: 12

Issue: 13

Pages: 731-741

Type: Article

DOI: 10.1016/J.MED.2016.06.003 DIALNET GOOGLE SCHOLAR

More publications in: Medicine: Programa de Formación Médica Continuada Acreditado

Sustainable development goals

Abstract

Introduction Hyperthyroidism is a condition in which the thyroid gland produces excessive thyroxin hormone. Epidemiology The prevalence is around 1.3%. When subclinical hyperthyroidism is included the prevalence raises to 6%. Causes Graves’ disease, toxic multinodular goiter and toxic adenoma are the most common causes of hyperthyroidism. Clinical findings The more prevalent symptoms are those related to the heart. Potential complications include high risk of atrial fibrillation and increased risk of osteoporosis. Diagnosis The diagnosis is based in the measurement of serum free T4, T3 and TSH. The evaluation of thyroid stimulating immunoglobulin, thyroid peroxidase, thyroglobulin antibodies, the thyroid scintigraphy, and ultrasound scan are useful in the differential diagnosis. Treatment Management of Graves’ disease includes treatment with antithyroid drugs, iodine-131 and thyroidectomy. The optimal approach depends on the etiology, specific patient clinical features, and patient preference.

Bibliographic References

  • Bahn Chair RS, Burch HB, Cooper DS, Garber JR, Greenlee MC, Klein I, et al. Hyperthyroidism and other causes of thyrotoxi-cosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid. 2011;21:593-646.
  • Davies TF, Reed Larsen P. Tirotoxicosis. En: Klonenberg HM, Melmed S, Polonsky KD, Reed Larsen P, editores. Williams Tratado de endocrinología. 11ª ed. Barcelona: Elsevier; 2009. p. 341-84.
  • Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, et al. Serum TSH, T(4), and thyroid antibodies in the Unit-ed States population (1988 to 1994): National Health and Nutrition Ex-amination Survey (NHANES III). J Clin Endocrinol Metab. 2002;87:489-99.
  • Vanderpump MP, Tunbridge WM, French JM, Appleton D, Bates D, Clark F, et al. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin Endocrinol (Oxf). 1995;43:55-68.
  • Kim YA, Park YJ. Prevalence and risk factors of subclinical thyroid dis-ease. Endocrinol Metab (Seoul). 2014;29:20-9.
  • Donangelo I, Braunstein GD. Update on subclinical hyperthy-roidism. Am Fam Physician. 2011;83:933-8.
  • Nystrom HF, Jansson S, Berg G. Incidence rate and clinical features of hyperthyroidism in a long-term iodine sufficient area of Sweden (Go-thenburg) 2003-2005. Clin Endocrinol (Oxf). 2013;78:768-76.
  • Brent GA. Clinical practice. Graves’ disease. N Engl J Med. 2008;358: 2594-605.
  • Davies TF, Yeo PP, Evered DC, Clark F, Smith BR, Hall R. Value of thyroid-stimulating-antibody determinations in predicting short-term thyrotoxic relapse in Graves’ disease. Lancet. 1977;1:1181-2.
  • Burch HB, Cooper DS. Management of Graves disease: a review. JAMA. 2015;314:2544-54.
  • Bartalena L, Fatourechi V. Extrathyroidal manifestations of Graves’ disease: a 2014 update. J Endocrinol Invest. 2014;37:691-700.
  • Bartalena L, Burch HB, Burman KD, Kahaly GJ. A 2013 European survey of clinical practice patterns in the management of Graves’ disease. Clin Endocrinol (Oxf). 2016;84:115-20.
  • Cooper DS. Antithyroid drugs. N Engl J Med. 2005;352:905-17.
  • Mitsiades N, Poulaki V, Tseleni-Balafouta S, Chrousos GP, Koutras DA. Fas ligand expression in thyroid follicular cells from patients with thion-amide-treated Graves’ disease. Thyroid. 2000;10:527-32.
  • Liu X, Qiang W, Liu L, Liu S, Gao A, Gao S, et al. A second course of antithyroid drug therapy for recurrent Graves’ disease: an experience in endocrine practice. Eur J Endocrinol. 2015;172:321-6.
  • Devereaux D, Tewelde SZ. Hyperthyroidism and thyrotoxicosis. Emerg Med Clin North Am. 2014;32:277-92.
  • Nayak B, Burman K. Thyrotoxicosis and thyroid storm. Endocri-nol Metab Clin North Am. 2006;35:663-86.
  • Díez JJ, Iglesias P, Donnay S. Thyroid dysfunction during pregnancy. Med Clin (Barc). 2015;145:344-9.
  • Prunty JJ, Heise CD, Chaffin DG. Graves’ disease pharmaco-therapy in women of reproductive age. Pharmacotherapy. 2016;36:64-83.
  • Krohn K, Fuhrer D, Bayer Y, Eszlinger M, Brauer V, Neumann S, et al. Molecular pathogenesis of euthyroid and toxic multinodular goiter. En-docr Rev. 2005;26:504-24.
  • Stanbury JB, Ermans AE, Bourdoux P, Todd C, Oken E, Tonglet R, et al. Iodine-induced hyperthyroidism: occurrence and epidemiology. Thyroid. 1998;8:83-100.
  • Harjai KJ, Licata AA. Effects of amiodarone on thyroid function. Ann Intern Med. 1997;126:63-73.
  • Beck-Peccoz P, Lania A, Beckers A, Chatterjee K, Wemeau JL. 2013 European thyroid association guidelines for the diagnosis and treatment of thyrotropin-secreting pituitary tumors. Eur Thyroid J. 2013;2:76-82.
  • Bernal J. Thyroid hormone resistance syndromes. Endocrinol Nutr. 2011;58:185-96.
  • Parkes IL, Schenker JG, Shufaro Y. Thyroid disorders during pregnancy. Gynecol Endocrinol. 2012;28:993-8.
  • Dunzendorfer T, de Las Morenas A, Kalir T, Levin RM. Struma ovarii and hyperthyroidism. Thyroid. 1999;9:499-502.
  • Giralt SA, Dexeus F, Amato R, Sella A, Logothetis C. Hyperthyroidism in men with germ cell tumors and high levels of beta-human chorionic go-nadotropin. Cancer. 1992;69:1286-90.
  • Vadiveloo T, Donnan PT, Cochrane L, Leese GP. The Thyroid Epidemiology, Audit, and Research Study (TEARS): the natural his-tory of endogenous subclinical hyperthyroidism. J Clin Endocrinol Metab. 2011;96:E1-8.
  • Schouten BJ, Brownlie BE, Frampton CM, Turner JG. Subclinical thyro-toxicosis in an outpatient population - predictors of outcome. Clin Endo-crinol (Oxf). 2011;74:257-61.
  • Das G, Ojewuyi TA, Baglioni P, Geen J, Premawardhana LD, Okosieme OE. Serum thyrotrophin at baseline predicts the natural course of subcli-nical hyperthyroidism. Clin Endocrinol (Oxf). 2012;77:146-51.
  • Biondi B, Bartalena L, Cooper DS, Hegedus L, Laurberg P, Ka-haly GJ. The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroi-dism. Eur Thyroid J. 2015;4:149-63.
  • Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NF, Cobin RH, et al. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA. 2004;291:228-38.
Data source: Dialnet